Paper40735995
Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.
Lin Q and 7 others. Curr Drug Deliv, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics. Papers, record 40735995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40735995
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sorafenib | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Polylactic Acid-Polyglycolic Acid Copolymer | Major topic |
| Liver Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Theranostic Nanomedicine | |
| Drug Liberation | |
| Cell Line, Tumor | |
| Cell Survival | |
| Drug Carriers | |
| Nanoparticles |
Source PubMed
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 2 | 36208844 | Global burden of primary liver cancer in 2020 and predictions to 2040. | J Hepatol | 2022 | https://conductscience.org/library/papers/36208844 | PubMed |
| 3 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 4 | 35989535 | The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. | Hepatology | 2023 | https://conductscience.org/library/papers/35989535 | PubMed |
| 5 | 37390855 | Diagnosis and monitoring of hepatocellular carcinoma in Hepatitis C virus patients using attenuated total reflection Fourier transform infrared spectroscopy. | Photodiagnosis Photodyn Ther | 2023 | https://conductscience.org/library/papers/37390855 | PubMed |
| 6 | 39095799 | Integrating bioinformatics and machine learning methods to analyze diagnostic biomarkers for HBV-induced hepatocellular carcinoma. | Diagn Pathol | 2024 | https://conductscience.org/library/papers/39095799 | PubMed |
| 7 | 33541087 | Epidemiology, mutational landscape and staging of hepatocellular carcinoma. | Chin Clin Oncol | 2021 | https://conductscience.org/library/papers/33541087 | PubMed |
| 8 | 38808046 | Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment. | Sisli Etfal Hastan Tip Bul | 2024 | https://conductscience.org/library/papers/38808046 | PubMed |
| 9 | 38149129 | A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma. | Cureus | 2023 | https://conductscience.org/library/papers/38149129 | PubMed |
| 10 | 34735916 | Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. | Int Immunopharmacol | 2021 | https://conductscience.org/library/papers/34735916 | PubMed |
| 11 | 35719048 | Research progress of gut microbiota in hepatocellular carcinoma. | J Clin Lab Anal | 2022 | https://conductscience.org/library/papers/35719048 | PubMed |
| 12 | 35126844 | Targets of immunotherapy for hepatocellular carcinoma: An update. | World J Hepatol | 2022 | https://conductscience.org/library/papers/35126844 | PubMed |
| 13 | 38195693 | New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma. | Acta Pharmacol Sin | 2024 | https://conductscience.org/library/papers/38195693 | PubMed |
| 14 | 36729264 | Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. | Cancer Metastasis Rev | 2023 | https://conductscience.org/library/papers/36729264 | PubMed |
| 15 | 38760445 | The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. | Br J Cancer | 2024 | https://conductscience.org/library/papers/38760445 | PubMed |
| 16 | 32549224 | Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32549224 | PubMed |
| 17 | 34291704 | Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. | J Chemother | 2022 | https://conductscience.org/library/papers/34291704 | PubMed |
| 18 | 39920399 | Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening. | Arch Pharm Res | 2025 | https://conductscience.org/library/papers/39920399 | PubMed |
| 19 | 36457288 | Aptamer-mediated hollow MnO2 for targeting the delivery of sorafenib. | Drug Deliv | 2023 | https://conductscience.org/library/papers/36457288 | PubMed |
| 20 | 38250308 | Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2024 | https://conductscience.org/library/papers/38250308 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42245685 | Nanomaterial-based strategies to overcome sorafenib resistance in hepatocellular carcinoma: from mechanistic insights to translational applications. | Front Oncol | 2026 | https://conductscience.org/library/papers/42245685 | PubMed |
| 41578333 | Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41578333 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40735995
GET https://conductscience.org/api/papers/v1/40735995/references?page=2